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Objective: Optimal platelet inhibition is an important therapeutic adjunct in patients with carotid artery stenosis
undergoing carotid artery stenting (CAS). Clopidogrel resistance is associated with increased periprocedural thrombo-
embolic complications from neurovascular stent placement procedures. The addition of cilostazol to dual antiplatelet
therapy (DAT) has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous
coronary intervention. This study was undertaken to evaluate the impact of adjunctive cilostazol in patients with CAS.
Methods: Platelet function was assessed by light transmittance aggregometry using the VerifyNow assay. Sixty-four
consecutive patients who underwent CAS received standard DAT, clopidogrel (75 mg daily), and aspirin (100 mg
daily) more than 4 weeks before the procedure. From 2010 to 2011 (period I), 28 patients underwent CAS under
standard DAT. From 2011 to 2013 (period II), 36 patients prospectively had preoperative assessment of platelet func-
tion, and 13 patients with clopidogrel resistance received adjunctive cilostazol (200 mg daily) in addition to standard
DAT. The incidence of new ipsilateral ischemic lesions on diffusion-weighted imaging a day after CAS and ischemic
or hemorrhagic events within 30 days was assessed.
Results: Clopidogrel resistance was indentiﬁed in 12 patients (43%) in period I and 13 patients (36%) in period II
(P [ .615). In period II, the addition of cilostazol signiﬁcantly decreased P2Y12 reaction units and % inhibition
(P [ .006 and P [ .005, respectively), and there was a signiﬁcant difference in P2Y12 reaction units between the two
periods. New ipsilateral ischemic lesions were signiﬁcantly decreased in period II (2/36 patients) compared with period I
(7/28 patients; P [ .034); however, there was no signiﬁcant difference in hemorrhagic and thromboembolic events
between the two periods.
Conclusions: Adjunctive cilostazol (triple antiplatelet therapy) in clopidogrel-resistant patients reduces the rate of clopi-
dogrel resistance and suppresses new ischemic lesions without hemorrhagic complications, as compared with standard
DAT. Antiplatelet management based on the evaluation of antiplatelet resistance would be required for prevention of
perioperative thromboembolic complications in CAS. (J Vasc Surg 2014;59:761-7.)Dual antiplatelet therapy (DAT) has become standard
pretreatment medication for carotid artery stenting
(CAS), and oral administration of aspirin and clopidogrel
is the standard regimen in most previous reports.1 Anti-
platelet agents are effective for reducing stent thrombosis
after CAS and for reducing the risk of vascular events in
other arterial beds, which provides a rationale for their
long-term use in these patients.2 However, the incidence
of periprocedural stroke was higher in patients treated with
CAS than in patients treated with carotid endarterectomythe Departments of Neurosurgerya and Radiology,b Nara Medical
niversity.
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vs Stenting Trial).3 Therefore, optimal platelet inhibition
may be an important therapeutic adjunct to suppress
ischemic events in patients with carotid artery stenosis
undergoing CAS.
Clopidogrel is a thienopyridine compound that antag-
onizes the adenosine diphosphate (ADP) receptor subtype,
P2Y12. It is a prodrug that ﬁrst exhibits antiplatelet activity
when it is activated via hepatic metabolism. Recent studies
have suggested that greater ADP-induced platelet inhibi-
tion by a more potent P2Y12 antagonist such as prasugrel,
cangrelor, and ticagrelor may result in greater reduction in
clinical ischemic events in the setting of percutaneous coro-
nary intervention (PCI).4 However, one important
problem with clopidogrel is the wide interindividual varia-
tion in its antiplatelet effect. Several studies have reported
periprocedural thromboembolic complications in neuro-
vascular and cardiovascular stent placement in patients
with clopidogrel resistance.5,6 Cilostazol is a selective
phosphodiesterase-3 inhibitor that is commonly used as
a vasodilator with antiplatelet activity in patients with761
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anti-inﬂammatory and antiapoptotic effects and to reduce
restenosis in patients after deployment of coronary or
carotid artery stents.7,8 The addition of cilostazol to DAT
has been reported to reduce platelet reactivity and to
improve clinical outcomes after PCI in previous studies9;
however, it has not clear whether preoperative adjunctive
cilostazol (triple antiplatelet therapy [TAT]) is useful in
clopidogrel-resistant patients treated with CAS for carotid
artery stenosis. Therefore, in the present study, we deter-
mined whether TAT with adjunctive cilostazol in
clopidogrel-resistant patients reduces perioperative throm-
boembolic complications and enhances platelet inhibition,
as compared with standard DAT.
METHODS
Inclusion criteria. The patients included in this study
were recruited from consecutive patients undergoing CAS
for carotid artery stenosis at Nara Medical University from
September 2010 to May 2013. The criteria for CAS were
stenosis >80% in asymptomatic lesions or >50% in symp-
tomatic lesions, lesions in patients who were at high risk
of CEA according to Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy
Trial (SAPPHIRE) criteria.10 Patients’ age, gender, past
history related to atherosclerosis, and preoperative medical
conditions were recorded. All patients underwent preop-
erative duplex sonography and magnetic resonance imaging
(MRI)/angiography, followed by cerebral angiography.
Vulnerable plaque was deﬁned as plaque composed of
intraplaque hemorrhage and lipid-rich/necrotic core based
on preoperative black-blood T1-weighted images and
T2-weighted images. All patients underwent diffusion-
weighted MRI (DWI) before CAS and the day after
CAS to evaluate the existence of new ipsilateral bright
spots, indicating a fresh embolic stroke due to the CAS
procedure.
Antiplatelet medications in two distinct periods.
Data were obtained during two distinct periods, with
different patients in each period. Period I was an observa-
tional period, and 28 patients were enrolled from
September 2010 to October 2011. These patients were
given two antiplatelet agents, aspirin 100 mg and clopidog-
rel 75 mg, starting more than 4 weeks before CAS. In addi-
tion, no antiplatelet management decisions were made
based on the platelet inhibition assay results. In period II,
36 patients were enrolled from November 2011 to May
2013. We prospectively subjected these patients to active
management of antiplatelet medications before CAS. These
patients were given two antiplatelet agents, aspirin
100 mg and clopidogrel 75 mg, starting more than 4 weeks
before CAS. However, patients who were resistant to
clopidogrel were given adjunctive cilostazol 200 mg
2 days before CAS.
Platelet function was analyzed using the VerifyNow
rapid platelet function assay (Accumetrics, San Diego,
Calif). This method was used to calculate aspirin reaction
units (ARU), P2Y12 reaction units (PRU), baseline(Base), and % inhibition. Based on previous reports, aspirin
resistance was deﬁned as ARU $550, whereas clopidogrel
resistance was deﬁned as PRU $240.11.11 All patients in
both groups had platelet function measured 2 days before
CAS and patients in period II had platelet function
measured again 1 week after CAS.
All patients signed a written authorization form that
allowed access to their medical records for research
purposes, and our institutional review board approved the
research protocol.
CAS procedure. All procedures were performed by
two specialist neurointerventionalists (I.N., T.W) certiﬁed
by the Japanese Society for Neuro-Endovascular Therapy.
Through the periods, the procedures were performed in
same protocol, technique, equipment, and physicians. CAS
was performed under local anesthesia. During the proce-
dure, heparin was given intravenously to maintain an acti-
vated clotting time of >275 seconds. After delivery of an
8-F guiding catheter into the common carotid artery, the
stenotic lesion was crossed with a guidewire, and a ﬁlter-
type embolic protection device (FilterWire EZ; Boston
Scientiﬁc, Natick, Mass) was inserted distal to the stenotic
lesion. The lesion was then predilated with a 3- or 4-mm-
diameter balloon, and the stent (Carotid Walstent; Boston
Scientiﬁc, Precise; Johnson & Johnson, New Brunswick,
NJ, or PROTÉGÉ; Covidien, Dublin, Ireland) was
deployed. Then, conservative postdilation was performed,
and the embolic protection device was removed. Conser-
vative postdilation was performed using an angioplasty
balloon with a diameter no greater than approximately 80%
of the normal luminal diameter distal to the stenosis, as
determined by intravascular sonography (Eagle Eye Gold:
Volcano Corporation, San Diego, Calif). When the slow
ﬂow phenomenon was observed, multiple aspirations of the
column of blood proximal to the ﬁlter were performed
using an aspiration catheter. Symptomatic ischemic events,
hemorrhagic events within 30 days and DWI abnormalities
were recorded during follow-up in each patient.
Evaluation of DWI. DWI was performed 1 day after
the procedure using a three-tesla system (Verio; Siemens,
Erlangen, Germany) with a multisection, single-shot, spin-
echo planar imaging sequence. Imaging parameters were as
follows: echo time, 100 ms; ﬁeld of view, 23 cm; matrix,
96  128; section thickness, 5 mm; and intersection gap,
1 mm. Apparent diffusion coefﬁcient maps were obtained
in all cases. The imaging protocol included same DWI
sequences before and after the procedure. All DWI scans
and apparent diffusion coefﬁcient maps were reviewed by
experienced neuroradiologists who were blinded to the
clinical information. A new ipsilateral hyperintense lesion
on DWI was considered an ischemic lesion caused by CAS-
related cerebral embolism.
Statistical analysis. All data are presented as mean 6
standard deviation. Differences between the two periods
were assessed using Fisher exact test. Patient age and
NASCET values were compared between the two periods
using a Student t-test. ARU, PRU, Base, and % inhibi-
tion were compared between the two periods using
Table I. General and lesion characteristics between two
periods
Variable
Patients, No. (%)
P
value
Period I
(n ¼ 28)
Period II
(n ¼ 36)
General characteristics
Mean age, years (range) 73 (58-83) 72 (58-88) .801
Females 4 (14%) 5 (20%) 1.000
Risk factor
Hypertension 20 (71%) 28 (78%) .576
Diabetes 6 (24%) 12 (36%) .403
Current smoker 4 (15%) 11 (32%) .149
Chronic kidney disease 9 (33%) 10 (29%) .786
Medications
Statins 22 (80%) 30 (86%) .375
Angiotensin receptor blockers 17 (61%) 24 (69%) .793
Proton pump inhibitors 5 (20%) 7 (21%) 1.000
Lesion characteristics
Symptomatic 12 (43%) 17 (48%) .803
Vulnerable plaque 7 (25%) 15 (42%) .193
Lesion side (left) 20 (71%) 19 (53%) 1.000
Degree of stenosis (%) 84 6 8 82 6 13 .984
Table II. General and lesion characteristics between
clopidogrel resistant and non-resistant patients
Variable
Patients, No. (%)
P
value
Clopidogrel
non-resistant
Clopidogrel-
resistant
Patients
(n ¼ 39)
Patients
(n ¼ 25)
General characteristics
Mean age (range) 71 (58-83) 74 (60-88) .205
Females 6 (15%) 3 (12%) 1.000
Risk factor
Hypertension 29 (72%) 19 (78%) 1.000
Diabetes 10 (26%) 8 (32%) .584
Current smoker 12 (28%) 3 (16%) .130
Chronic kidney disease 13 (33%) 6 (24%) .577
Medications
Statins 34 (87%) 22 (88%) 1.000
Angiotensin receptor
blockers
27 (69%) 16 (64%) .786
Proton pump inhibitors 6 (15%) 6 (24%) .514
Lesion characteristics
Symptomatic 17 (44%) 12 (48%) .800
Vulnerable plaque 14 (36%) 8 (32%) .793
Lesion side (left) 25 (64%) 14 (56%) .603
Degree of stenosis (%) 82 6 12 84 6 9 .858
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med at P < .05.
RESULTS
Sixty-four patients participated in the study (55 males,
9 females; mean age, 72 years old). In period I (28
patients), the mean age was 73 years old (range, 58-
83 years old). Fourteen percent of the patients were
women. In period II (36 patients), the mean age was
72 years old (range, 58-88 years old). Five percent of
the patients were women. Baseline characteristics were
well matched between the study periods. There were no
signiﬁcant differences in risk factors, medications, and
lesion characteristics including symptomatic, vulnerable
plaque, lesion side, and degree of stenosis according to
NASCET between the two periods (Table I). Before
CAS, DWI showed ipsilateral acute ischemic cerebral
lesions in ﬁve patients (18%) in period I and 6 patients
(17%) in period II. Table II shows the differences in
general and lesion characteristics between clopidogrel-
resistant patients and non-resistant patients. There were
no signiﬁcant differences between the group. Twenty-
one patients (75%) in period I and 21 patients (58%) in
period II were treated with closed-cell stents. There
were no signiﬁcant differences in stent design between
the two periods. All procedures were performed using
a ﬁlter-type embolic protection device (FilterWire EZ;
Boston Scientiﬁc; Table III).
Resistance to aspirin and clopidogrel. The results for
ARU and PRU before adjunctive cilostazol are shown in
Table IV. Four patients (14%) in period I and 4 patients
(11%) in period II were aspirin-resistant (P ¼ .721),
whereas 12 patients (43%) in period I and 13 patients
(36%) in period II were clopidogrel-resistant (P ¼ .615).
The mean ARU was 477 6 83 in period I and 460 6 70 in
period II (P ¼ .391). The mean PRU, Base, and % inhi-
bition were 235 6 71, 300 6 38, and 22 6 20 in period I,
and 223 6 75, 305 6 48, and 28 6 21 in period II,
respectively. The differences in these parameters between
the two periods were not signiﬁcant (Table IV).
Effect of adjunctive cilostazol. The results for ARU,
PRU, Base, and % inhibition a week after adjunctive cilos-
tazol for clopidogrel resistance were 457 6 65, 201 6 63,
309 6 50, and 35 6 18 in period II (n ¼ 36), respectively.
There were signiﬁcant difference in PRU and % inhibition
between period I (without cilostazol) and period II (with
cilostazol; P ¼ .044 and P ¼ .002, respectively). Further-
more, the results for ARU and PRU before and after
adjunctive cilostazol in patients with clopidogrel resistance
in period II (n ¼ 13), there were no signiﬁcant differences
in ARU (493 6 77, 498 6 71; P ¼ .876) and Base (328 6
41, 337 6 40; P ¼ .943); however, PRU was signiﬁcantly
lower (300 6 36, 240 6 62; P ¼ .006) and % inhibition
was signiﬁcantly higher (8.8 6 8.7, 28 6 18; P ¼ .005)
after adjunctive cilostazol. There were no symptomatic
thromboembolic or hemorrhagic events in either group;
however, new ipsilateral ischemic lesions were signiﬁcantly
decreased in period II (two of 36 patients) compared withperiod I (seven of 28 patients; P ¼ .034; Table III). In
period I, there was a single lesion in two patients, and there
were multiple lesions; three patients with two lesions, one
patient with three lesions, and one patient with ﬁve lesions.
There was one patient with a single lesion and one patient
with two lesions in period II. Furthermore, in seven
patients who presented new ipsilateral ischemic lesions after
CAS in period I, there were three of seven patients with
Table III. Carotid artery stenting (CAS) procedure and
ischemic/hemorrhagic events
Variable
Patients, No. (%)
P
value
Period I
(n ¼ 28)
Period II
(n ¼ 36)
Stent
Closed-cell 21 (75%) 21 (58%) .193
Open-cell 7 (25%) 15 (43%) .193
EPD (ﬁlter type) 28 (100%) 36 (100%) 1.000
Slow ﬂow phenomenon 3 (11%) 3 (9%) 1.000
DWI positive 7 (23%) 2 (6%) .034a
Ischemic events 0 (0%) 0 (0%) 1.000
Hemorrhagic events 0 (0%) 0 (0%) 1.000
DWI, Diffusion-weighted imaging; EPD, embolic protection device.
aP < .05.
Table IV. Baseline platelet reactivity and resistance to
antiplatelet agents
Variable
Patients, No. (%)
P
value
Period I
(n ¼ 28)
Period II
(n ¼ 36)
VerifyNow assay
ARU 477 6 83 460 6 70 .391
PRU 235 6 71 223 6 75 .494
Base 300 6 38 305 6 48 .653
% inhibition 22 6 20 28 6 21 .226
Resistance to antiplatelet
therapy
Aspirin 4 (14%) 4 (11%) .721
Clopidogrel 12 (43%) 13 (36%) .615
ARU, Aspirin reactive units; PRU, P2Y12 reactive units.
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resistance.
DISCUSSION
In the present study, we prospectively introduced
a preoperative management protocol for patients with clo-
pidogrel resistance to prevent perioperative thromboem-
bolic complications and DWI abnormalities in CAS. We
demonstrated for the ﬁrst time that adjunctive cilostazol
in patients with clopidogrel resistance suppresses the
frequency of new cerebral ischemic lesions without
increasing of hemorrhagic complications, reduces the rate
of clopidogrel resistance, and intensiﬁes platelet inhibition
as compared with standard DAT.
Clopidogrel resistance and monitoring platelet
inhibition. Recently, it has been demonstrated that clopi-
dogrel has wide interindividual variation in its antiplatelet
effect, and several factors play a role, including drug compli-
ance, bioavailability, genetic polymorphisms, and drug inter-
actions. Clopidogrel is a prodrug that requires metabolic
conversion to an active metabolite that inhibits ADP-
induced platelet activation and aggregation. The biotrans-
formation of clopidogrel requires several cytochrome P450(CYP) isoenzymes and CYP2C19.12 CYP2C19*2 has
been identiﬁed as a major determinant of the serum
concentration of the active metabolite of clopidogrel and
the effects of clopidogrel on the inhibition of platelet
aggregation. Furthermore, CYP2C19*2 is associated with
cardiovascular events in patients taking clopidogrel
following PCI.13 Recently, East Asians were shown to
carry the CYP 2C19 loss-of-function (LOF) allele more
often than Caucasians. The inﬂuence of the CYP2C19
LOF allele on the clopidogrel response and clinical
outcomes in East Asians with acute myocardial infarction
(AMI) has been reported.14
With the recent development of a point-of-care assay
for the antiplatelet monitoring (VerifyNow), it has become
quite easy and convenient to monitor the antiplatelet func-
tion of both aspirin and clopidogrel, and this assay has
become widely used in daily practice instead of light trans-
mission aggregometry. VerifyNow is a cartridge-based
platelet function analyzer that uses a modiﬁed light trans-
mission aggregometry paradigm to assess inhibition of
platelet function in response to stimulation with different
platelet agonists, depending on the cartridge used. This
method has shown excellent correlations with optical
aggregometry for aspirin15 and clopidogrel,16 although
the P2Y12-independent pathways were not assessed using
this device. However, there are no standard deﬁnitions of
clopidogrel resistance, and there is large variability in the
cut-off values of both PRU (range, 175-240) and
percentage inhibition (20% or 40%) that have been used
to deﬁne clopidogrel resistance.13 The optimal cut-off
value for Asians might need to be modiﬁed based on
the high prevalence of the CYP2C19 LOF allele, as
described above.
Effect of adjunctive cilostazol. A recent randomized
controlled clinical trial reported that cilostazol was not infe-
rior to aspirin for the prevention of recurrent stroke, which
can be ascribed not only to the antiplatelet effect but also
to improvement of endothelial function, dilation of blood
vessels by increased production of nitric oxide, endogenous
vasodilating factor, and reduction of intracellular calcium
ion concentrations.17,18 Furthermore, cilostazol was
associated with fewer hemorrhagic complications.17,18
Cilostazol was shown to improve platelet responsiveness
to clopidogrel in AMI patients who underwent PCI.19
Moreover, the addition of cilostazol to aspirin and clopi-
dogrel results in greater inhibition of platelet aggregation
in patients with non-ST elevation acute coronary syndrome
or AMI than standard DAT20,21 or high maintenance
clopidogrel (150 mg/day) plus aspirin treatment.14 TAT
was associated with a signiﬁcant reduction in in-hospital
mortality and 8-month clinical outcomes, and TAT
signiﬁcantly lowered the risk of the 30-day and 1-year
composite endpoint of cardiac death, AMI, and stroke in
acute coronary syndrome patients who underwent coro-
nary stenting.22 In a meta-analysis of TAT using cilostazol,
TAT was associated with a signiﬁcant reduction in the risk
of major adverse cardiac events compared with DAT. The
addition of cilostazol to standard aspirin and clopidogrel
Fig. Pathways involved in platelet aggregation and possible
mechanism involved in response to clopidogrel and cilostazol.
Solid arrows indicate activation and dotted arrows indicate inhibi-
tion. AC, Adenylate cyclase; ADP, adenosine diphosphate; cAMP,
cyclic adenosine monophosphate; CYP, cytochrome P; Gi, inhib-
itory G protein; PDE, phosphodiesterase; PKA, protein kinase A;
VASP, vasodilator-stimulated phosphoprotein.
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venting major adverse cardiac events after coronary stent-
ing, especially in high-risk patients.9 In the present study,
we demonstrated for the ﬁrst time that adjunctive cilostazol
in patients with clopidogrel resistance suppresses the
frequency of new cerebral ischemic lesions without
increasing hemorrhagic complications in patients under-
going CAS.
Mechanism of action of clopidogrel and cilostazol
for ADP-induced platelet activation is thought to be as
follows. P2Y12 are G-protein-coupled receptors where
ADP acts as the agonist. Activation of the P2Y12 by
ADP results in inhibition of adenylate cyclase and reduc-
tion of cyclic adenosine monophosphate (cAMP) levels.
The reduction of cAMP results in decreased phosphoryla-
tion of vasodilator-stimulated phosphoprotein, leading to
increased platelet activation. When clopidogrel blocks the
binding of ADP to P2Y12 receptors on platelets, adeny-
late cyclase activity is increased, resulting in the synthesis
of cAMP. The cAMP-dependent protein kinase A that is
activated by cAMP is inactivated by vasodilator-stimulated
phosphoprotein, and this causes inhibition of platelet
aggregation. Cilostazol enhances cAMP within platelets
by blocking phosphodiesterase-3A. Therefore, since
both clopidogrel and cilostazol augment cAMP in the
signal transduction pathway from P2Y12 receptors, the
combined use of the two drugs augments the inhibition
of ADP-induced platelet aggregation (Fig).23
DWI abnormalities after CAS. New DWI lesions
that show clinically silent embolic lesions after protected
CAS have been reported over a wide range, from 17% to
73%.24-27 Barbato et al report the appearance of new ipsi-
lateral ischemic lesions in 67% of 36 patients after ﬁlter-
protected CAS.24 Pinero et al detected new ipsilateral
lesions in 22 patients (14%) undergoing CAS with ﬁlter
protection, and in 15 of them (54%), there was a single
lesion; in 13 (46%), there were multiple lesions; three
patients with two lesions, six patients with three lesions,
two patients with four lesions, one patient with ﬁve lesions,
and one patient with six lesions.26 The rate of new DWI
lesions in our study was lower compared with these other
studies. In the present study, 25% (seven of 28) patients in
period I and 6% (two of 36) in period II had new ischemic
lesions detected by DWI in the treated vascular territory
after CAS with distal ﬁlter protection. Recently, a lower
incidence of ipsilateral new DWI lesions after ﬁlter-
protected CAS (8.51%) was reported,28 and the type of
embolic protection device did not inﬂuence the clinical
outcome after CAS.29 Most previous studies used standard
DWI with a section thickness of 5 to 6 mm. The rate of
lesions detected may have been affected by the section
thickness of DWI. In the present study, no patients
developed symptomatic thromboembolic events within
30 days of CAS in either group; however, new asymp-
tomatic ischemic lesions might lead to clinical conse-
quences over the long term, including cognitive decline
and dementia.30 The detection of small ischemic lesions
after CAS may be important for patient prognosis.Risk of TAT. Previous studies have demonstrated that
cilostazol does not prolong bleeding time when compared
with aspirin, thienopyridines, or various combinations of
these drugs.18,31 The risk of serious bleeding after TAT
was not signiﬁcantly higher than with DAT. In a meta-
analysis, only 1.9% of patients who received TAT devel-
oped major bleeding events.7 However, the risk of
gastrointestinal complications was increased signiﬁcantly in
the TAT group (increased by nearly 1.5 times), which
should be taken into account in clinical practice, especially
in older patients with a history of peptic ulcer and gastro-
intestinal hemorrhage.22 Therefore, we emphasize that
preoperative platelet reactivity should be measured to select
patients who may need cilostazol and to exclude those at
high risk of hemorrhagic complications. We suggest that
selective adjunctive cilostazol increases platelet inhibition
and prevents new cerebral ischemic events without
hemorrhagic complications in CAS procedures.
Study limitations. The present study has several limi-
tations. First, the study design was nonrandomized in
nature, and the small sample size may have introduced
patient selection bias. Second, the study group was classi-
ﬁed by chronological order, other factors including
learning curve may have contributed to a lower incidence
of new ischemic lesions in period II. Third, we measured
platelet reactivity with only one method, the VerifyNow
P2Y12 assay. Fourth, this study did not access the
CYP2C19 LOF allele. The CYP2C19 LOF allele may
inﬂuence the clopidogrel response and clinical outcomes
in East Asians. Fifth, there were only 13 patients treated
with TAT. A larger study examining the safety and efﬁcacy
of TAT in clopidogrel-resistant patients undergoing
CAS is required. For further evaluation, a randomized,
JOURNAL OF VASCULAR SURGERY
766 Nakagawa et al March 2014multicenter, prospective study involving a greater number
of patients is required to clarify the signiﬁcance of antipla-
telet resistance in CAS.
CONCLUSIONS
We demonstrated that adjunctive cilostazol in patients
that did not have an adequate response to clopidogrel
suppressed the frequency of cerebral ischemic lesions
without hemorrhagic complications and reduced the rate
of clopidogrel resistance and enhanced platelet inhibition,
as compared with standard DAT. We recommend that
antiplatelet management should be based on the evaluation
of antiplatelet resistance for prevention of perioperative
thromboembolic and hemorrhagic events in CAS.
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